Juno Therapeutics (NASDAQ:JUNO)‘s stock had its “buy” rating restated by investment analysts at Raymond James Financial in a research report issued to clients and investors on Monday.

A number of other brokerages have also issued reports on JUNO. Cowen restated a “buy” rating on shares of Juno Therapeutics in a research note on Friday, November 3rd. Zacks Investment Research lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Wells Fargo & Company lowered shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Citigroup restated a “buy” rating and issued a $59.00 target price on shares of Juno Therapeutics in a research note on Tuesday, October 31st. Finally, SunTrust Banks upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 2nd. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $45.48.

Juno Therapeutics (NASDAQ:JUNO) opened at $50.24 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics has a 12-month low of $17.52 and a 12-month high of $63.45.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.07. The company had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The firm’s revenue for the quarter was up 115.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.57) EPS. equities analysts forecast that Juno Therapeutics will post -4.02 EPS for the current fiscal year.

In related news, General Counsel Bernard J. Cassidy sold 28,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $44.92, for a total transaction of $1,257,760.00. Following the completion of the sale, the general counsel now directly owns 55,970 shares in the company, valued at $2,514,172.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Robert Azelby sold 12,850 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $44.95, for a total transaction of $577,607.50. Following the sale, the executive vice president now owns 37,439 shares of the company’s stock, valued at $1,682,883.05. The disclosure for this sale can be found here. Insiders sold 54,801 shares of company stock worth $2,527,741 in the last 90 days. 15.08% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of JUNO. Advisor Group Inc. lifted its position in shares of Juno Therapeutics by 141.1% in the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,439 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares in the last quarter. Rockefeller Financial Services Inc. lifted its position in Juno Therapeutics by 1,433.2% in the 3rd quarter. Rockefeller Financial Services Inc. now owns 3,465 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 3,239 shares in the last quarter. Pacad Investment Ltd. purchased a new stake in Juno Therapeutics in the 2nd quarter worth approximately $105,000. Finally, Bronfman E.L. Rothschild L.P. lifted its position in Juno Therapeutics by 27,376.9% in the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 3,559 shares in the last quarter. Hedge funds and other institutional investors own 70.37% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/12/juno-therapeutics-juno-buy-rating-reiterated-at-raymond-james-financial.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.